Gene-sequencing hardware and software giant Illumina is expanding to consumer-facing tests—and perhaps even brand partnerships.
A simple blood test to detect early signs of cancer. A noninvasive way to screen pregnancies for common genetic conditions. An app store for your genetic information. Illumina, a San Diego-based gene-sequencing hardware and software behemoth with a market capitalization of $22 billion, is working on all these initiatives—and more.
